https://www.selleckchem.com/pr....oducts/Rapamycin.htm
BACKGROUND The safety of CAS in elderly patients remains controversial. And the aims of this study were to evaluate 30-day outcomes after CAS in elderly patients (≥70 years) and to investigate the risk factors for the postoperative incidence of major adverse clinical events (MACEs) for providing clinical evidence to improve CAS safety in this specific subgroup of patients. METHODS Our data set included patients who underwent CAS between 2001 and 2017 at Xuanwu Hospital, Capital Medical University. The primary outcome variable was 30-d